Evidence map›Paper›PMID 23382471›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013

Clinicopathologic findings predictive of relapse in children with stage III favorable-histology Wilms tumor.

Peter F Ehrlich, James R Anderson, Michael L Ritchey, Jeffrey S Dome, Daniel M Green, Paul E Grundy, Elizabeth J Perlman, John A Kalapurakal, Norman E Breslow, Robert C Shamberger

Open access · bronzeAbstract read
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 98 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Localized Wilms' tumor in low-middle-income countries (LMIC): how can we get better?Journal of the Egyptian National Cancer Institute · 2020
    Article
  17. Article
  18. Article
  19. Article
  20. Imaging of Wilms tumor: an update.Pediatric radiology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Peter F EhrlichUniversity of Michigan, Ann Arbor, MI 48109, USA. pehrlich@med.umich.edu
James R Anderson
Michael L Ritchey
Jeffrey S Dome
Daniel M Green
Paul E Grundy
Elizabeth J Perlman
John A Kalapurakal
Norman E Breslow
Robert C Shamberger
University of Nebraska–Lincoln · US

Funding

COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
Late Effects of Treatment in Wilms Tumor Survivors and OffspringR01CA054498 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEISENRING, WENDY M · 1991 to 2017
$13.8M
NWTSG Foreign AccrualU10CA042326 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI GREEN, DANIEL MICHAEL · 1985 to 2003
$2.8M
NCI NIH HHS CA42326NCI NIH HHS CA98543NCI NIH HHS R01 CA054498NCI NIH HHS U10 CA098543
6 · The paper itself

Abstract

purposeStage III designation in NWTS-5 (National Wilms Tumor Study-5) was determined by four pathologic criteria: positive lymph nodes (LNs), peritoneal implants, residual disease, and tumor rupture. The objective of this study was to determine the prognostic significance of each of the stage III criteria. PATIENTS AND

methodsChildren with stage III Wilms tumor (WT) treated in NWTS-5 were assessed for event-free (EFS) and overall survival (OS). Sites of relapse and molecular status of tumors are reported. EFS and OS are reported 8 years after diagnosis.

resultsThere were 569 patients with local stage III favorable-histology (FH) WT in this analysis, of whom 109 had overall stage IV disease. LN involvement alone was the most frequent criterion for stage III designation (38%), followed by microscopic residual disease alone (20%), microscopic residual disease and LN involvement (14%), and spill or soilage alone (9%). The 8-year EFS and OS estimates for all patients with local stage III FHWT were 82% and 91%, respectively. Multivariate analysis demonstrated that both LN involvement (relative risk, 1.89; P = .005) and microscopic residual disease (relative risk, 1.87; P = .007) were predictive of EFS, and OS results were similar. There was no apparent difference in pattern of relapse according to stage III subtype. The rate of loss of heterozygosity was higher (6%) for those with positive LNs than for those without (2%; P = .05).

conclusionLN involvement and microscopic residual are the stage III criteria highly predictive of EFS and OS for patients with stage III FHWT. It is possible that in future studies, patients with different stage III criteria may receive different therapies.

Indexed as

ChildForecastingHumansKidney NeoplasmsLymphatic MetastasisNeoplasm Recurrence, LocalNeoplasm StagingWilms Tumor

Identifiers

PMID23382471
PMCPMC3595426
OpenAlexW2118094790

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.